DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Vir Biotechnology's - 1 sotrovimab - 1 Cowen - 1 Phil Nadeau - 1 Nadeau - 1 Leroy Leo - 1 Shailesh - 1
Top related locs:
Bengaluru
Top related orgs:
GSK plc - 1 COVID - 1 Alnylam Pharmaceuticals - 1 Vertex Pharmaceuticals - 1 Thomson - 1

Search resuls for: "Vir Biotechnology's"


3 mentions found


☆ Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial
  + stars: | 2023-07-20 | by ( ) www.reuters.com   time to read: +1 min
July 20 (Reuters) - Vir Biotechnology's (VIR.O) shares plunged 45% to a more than three-year low on Thursday after the company's experimental antibody therapy to prevent a type of flu failed to meet its goals in a mid-stage trial. The biotechnology firm, which came into prominence through its COVID-19 antibody therapy sotrovimab developed in partnership with GSK plc (GSK.L), lost over $1 billion in market capitalization in early trade hit by the therapy's failure. The company said it will conduct further analyses on the trial data to "better understand these outcomes", but TD Cowen analyst Phil Nadeau does not expect the therapy to undergo further development. The company is developing antibody therapies against hepatitis B and D, for which data is expected later this year, and also has development programs for COVID-19, HIV and influenza. Reporting by Leroy Leo in Bengaluru; Editing by Shailesh KuberOur Standards: The Thomson Reuters Trust Principles.
Persons: Vir Biotechnology's, sotrovimab, Cowen, Phil Nadeau, Nadeau, Leroy Leo, Shailesh Organizations: GSK plc, COVID, Alnylam Pharmaceuticals, Vertex Pharmaceuticals, Thomson Locations: Bengaluru
☆ Britain's NICE recommends against NHS use of 5 COVID treatments as not cost-effective
  + stars: | 2022-11-16 | by ( Maggie Fick | ) www.reuters.com   time to read: +3 min
The review, conducted by the National Institute for Health and Care Excellence (NICE) and published on Wednesday, is its first involving COVID-19 treatments as the pandemic enters a new phase. The recommendations are a draft, NICE said, and until final guidance is published, access to COVID-19 medicines will continue as is. NICE acknowledged that there is evidence that Merck's molnupiravir and Gilead Sciences Inc's (GILD.O) hospital-administered antiviral remdesivir are effective at treating COVID-19. It also recommended against three other COVID treatments, including GSK (GSK.L) and partner Vir Biotechnology's (VIR.O) sotrovimab, an antibody therapy that the World Health Organization recommended against in September. One expert said that some of the COVID treatments NICE recommended against are an important part of the British government's current strategy.
☆ WHO 'strongly advises against' use of two COVID treatments
  + stars: | 2022-09-15 | by ( Natalie Grover | ) www.reuters.com   time to read: +3 min
A woman holds a small bottle labelled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in this illustration taken October 30, 2020. The virus has since evolved, and mounting evidence from lab tests suggests the two therapies - sotrovimab as well as casirivimab-imdevimab - have limited clinical activity against the latest iterations of the virus. Another COVID therapy that emerged early in pandemic was Gilead's (GILD.O) antiviral remdesivir. The WHO expanded its conditional recommendation for the drug, advising that it can be used in patients with severe COVID as well as non-severe COVID patients at the highest risk of hospitalization. There are a handful of existing COVID therapeutics that remain useful in the fight against the virus, and others in development that are expected to also benefit patients.
0 next >>
Total: 3